Sign In
Buy OMER
$10.16
-0.1000 (-0.97%)
At Close: Jun 03, 2026
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
04:11pm, Monday, 11'th Nov 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024
Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript
01:05am, Saturday, 10'th Aug 2024
Omeros Corporation (NASDAQ:OMER ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jennifer Cook Williams - Investor Relations, Cook Williams Communications, Inc
Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024
04:02pm, Monday, 05'th Aug 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2024, on Wednesday, August 7, 2024, after
Omeros Announces Webcast Details for Annual Meeting of Shareholders
09:00am, Tuesday, 04'th Jun 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, J
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has completed a series of strategic financial transactions, further strengthening its balance sheet and extending th
Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript
07:23pm, Wednesday, 15'th May 2024
Omeros Corporation (NASDAQ:OMER ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and Chief Executive Off
Omeros Corporation Reports First Quarter 2024 Financial Results
04:02pm, Wednesday, 15'th May 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
08:50am, Friday, 10'th May 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended March 31, 2024, on Wednesday, May 15, 2024
Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript
08:09pm, Monday, 01'st Apr 2024
Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
08:30am, Wednesday, 27'th Mar 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 202
Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade
10:02am, Sunday, 17'th Mar 2024
Hidden gems often remain undiscovered within the labyrinth of the stock market. Three stocks with massive upside stand out among the several alternatives as possible titans with significant upside pot
3 Sleeper Stocks Under $15 Ready to Explode by 2029
09:34am, Wednesday, 07'th Feb 2024
In general, high-growth stocks and sleeper stocks under $15 are associated with valuation concerns. Let's forget inflated giants and overhyped darlings.
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
09:11am, Thursday, 01'st Feb 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded in
7 Short-Squeeze Stocks That Are Screaming for Speculation
01:08pm, Sunday, 24'th Dec 2023
While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it's time to address this speculative p
Omeros: Why It Is Worthwhile To Bet On Narsoplimab
01:18am, Monday, 27'th Nov 2023
Omeros Corporation focuses on small-molecule and antibody drugs for common disorders and rare diseases. The company has prioritized the resubmission of its BLA for Narsoplimab for TA-TMA treatment and
